950220 — Neoimmunetech Balance Sheet
0.000.00%
Last trade - 00:00- KR₩146bn
- KR₩88bn
Annual balance sheet for Neoimmunetech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 93.3 | 65.5 | 130 | 92.4 | 53.6 |
| Total Other Current Assets | |||||
| Total Current Assets | 94.7 | 74.1 | 141 | 93.1 | 56 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.66 | 3.73 | 7.64 | 7.41 | 6.01 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 105 | 87.9 | 158 | 110 | 70.2 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.6 | 8.27 | 17.2 | 12.9 | 9.99 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 4.65 | 10.5 | 21.1 | 15.9 | 12.1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 100 | 77.4 | 137 | 94.4 | 58.1 |
| Total Liabilities & Shareholders' Equity | 105 | 87.9 | 158 | 110 | 70.2 |
| Total Common Shares Outstanding |